-
Nano Letters: Peking University makes progress in tumor nanovaccine research!
Time of Update: 2022-04-24
Recently, the academic journal Nano Letters published online the latest research results of Wang Yiguang's research team from the State Key Laboratory of Natural and Biomimetic Medicine, School of Pharmacy, Peking University, "A pH-/enzyme-responsive nanoparticle selectively targets endosomal Toll-like receptors to potentiate robust cancer vaccination.
-
Front Oncol: Combined radiotherapy on the basis of chemotherapy can improve the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma
Time of Update: 2022-04-24
The aim of this study was to evaluate the efficacy of chemotherapy combined with radiotherapy (CRT) versus chemotherapy alone (CT) in patients with locally advanced or metastatic esophageal squamous cell carcinoma .
-
Front Oncol: Domestic multi-center evaluation of the efficacy of Regorafenib (regorafenib) third-line or above in the treatment of patients with refractory metastatic colorectal cancer (mCRC)
Time of Update: 2022-04-24
The study included patients with refractory metastatic colorectal cancer (mCRC) from 4 centers in China between February 1, 2018 and June 31, 2021, divided into 3 groups: regorafenib monotherapy, regorafenib Combined chemotherapy group and regorafenib combined with anti-PD-1 treatment group .
-
CAR-T cell therapy Yescarta wins FDA approval for early-stage lymphoma treatment
Time of Update: 2022-04-24
lymphomaGilead Sciences announced today that the FDA has expanded the approval of Yescarta (axicabtagene ciloleucel) to include patients with large B-cell lymphoma (LBCL) who are refractory to first-line chemoimmunotherapy or who have relapsed within 12 months of first-line chemoimmunotherapy .
-
Cancer: Safety and efficacy of nivolumab combined with ipilimumab in patients with advanced renal cell carcinoma with brain metastases (CheckMate 920)
Time of Update: 2022-04-24
CheckMate 920 is a prospective, nonrandomized, open-label, multi-cohort, Phase 3b/4 clinical trial evaluating nivolumab (nivolumab) in combination with ipilimumab (ipilimumab) in previously untreated advanced renal disease Efficacy in patients with cell carcinoma (aRCC) or metastatic RCC .
-
Clin Cancer Res: A biomarker that can predict the prognosis of patients with advanced liver cancer treated with sintilimab + IBI305
Time of Update: 2022-04-24
Blood vesselThis study aimed to explore the efficacy and safety of the anti-PD-1 antibody sintilimab combined with bevacizumab biosimilar IBI305 in the treatment of advanced hepatocellular carcinoma, and related biomarkers .
-
Two Phase III studies of NKTR-214 in combination with Opdivo in melanoma failed (PIVOT IO-001)
Time of Update: 2022-04-24
In addition, based on the results of the independent Data Monitoring Committee (DMC) review of the PIVOT IO-001 study, the companies also decided to discontinue enrollment and unblind the ongoing Phase III PIVOT-12 study in adjuvant melanoma, which is designed to evaluate Adjuvant immunotherapy efficacy of NKTR-214 plus nivolumab versus nivolumab alone after complete resection of melanoma in patients at high risk of recurrence .
-
European Radiology: How to choose the surgical method for thyroglossal duct cyst?
Time of Update: 2022-04-24
According to previous studies, EA has a high success rate in the treatment of TGDC, with a mean volume reduction rate (VRR) of 75-82% at the final follow-up examination .
-
PeerJ: The risk of esophageal cancer can be 4 times worse by changing the type of fat intake?
Time of Update: 2022-04-24
The association between MLC-SFA patterns and ESCC risk was different when stratified by fried foods ( I 2 = 75.
The association between MLC-SFA patterns and ESCC risk was different when stratified by fried foods ( I 2 = 75.
-
Clin Cancer Res: Avelumab + Trabectedin Combination for Advanced Fat/Leiomyosarcoma
Time of Update: 2022-04-24
This study is a single-arm, open-label, Phase 1/2 trial to evaluate the efficacy and safety of trabectedin in combination with the anti-PD-L1 antibody Avelumab in the treatment of advanced leiomyosarcoma and liposarcoma .
-
Eur Urol Focus: Robot-Assisted Versus Laparoscopic Radical Prostate Surgery: 12-Month Results from the Multicenter Randomized Controlled LAP-01 Trial
Time of Update: 2022-04-24
In the present trial, they further compared RARP and LRP for voiding capacity, sexual intercourse, and oncological outcomes at 12 months of follow-up .
RARP and LRP were further compared for voiding capacity, sexual intercourse, and oncological outcomes at 12-month follow-up .
-
JAMA Oncol: Paclitaxel + cisplatin + capecitabine induction chemotherapy improves survival in patients with advanced nasopharyngeal carcinoma
Time of Update: 2022-04-24
In conclusion, this randomized trial showed that compared with induction chemotherapy with PF regimen, two courses of induction therapy with TPC regimen can improve the treatment failure-free survival rate of patients with stage IVA-IVB nasopharyngeal carcinoma without increasing toxicity .
-
Br J Dermatol: Basal cell carcinoma in older adults: how to decide when to actively monitor or wait vigilantly
Time of Update: 2022-04-24
An interesting point recently published in JAMA recommends active surveillance as a treatment option for low-risk basal cell carcinoma .
In this strategy, it is still important to inform patients and their GPs when to contact a dermatologist (rapid growth, symptomatic basal cell carcinoma, psychological burden) .
-
European Radiology: For thyroid cancer patients, which lymph nodes are at risk of metastasis?
Time of Update: 2022-04-24
Sonographic features suggestive of abnormal metastatic LN include disappearance of fat mounds, round rather than oval shape, cystic changes, calcifications, and increased peripheral blood vessels .
Performing FNA on indeterminate LNs in patients with primary tumors showing ETE or non-parallel orientations may improve diagnostic performance and reduce the rate of unnecessary FNA .
-
LANCET: Don't eat too salty, high salt makes China's death the first in the world
Time of Update: 2022-04-24
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trialThe study re -emphasized that a low-salt diet, reducing sodium intake could reduce the risk of death or hospitalization and improve overall quality of life .
-
Nature Cancer: LCOR mRNA therapy combined with PD-L1 inhibitor successfully challenges triple-negative breast cancer
Time of Update: 2022-04-24
immune tumor immunity Source: Nature CancerSource: Nature Cancer A team from the Hospital del Mar Medical Research Institute found that in triple-negative breast cancer (TNBC), cancer stem cells are able to evade the immune system, and that increased expression levels of a protein called LCOR (ligand-dependent corepressor) can interfere with this.
-
ELCC 2022: Summary of Clinical Research on Innovative Drugs
Time of Update: 2022-04-24
The ORIENT-11 study found that on the basis of first-line pemetrexed and platinum-based chemotherapy, the combination of sintilimab could improve PFS in patients with advanced non-squamous and non-small cell lung cancer.
-
Chinese medicine reverses multidrug resistance in cancer and its mechanism
Time of Update: 2022-04-24
These mechanisms play a key role in the development of several MDR-reversing agents: aberrant expression of cell membrane transporters, adaptation of cancer cells to the microenvironment, regulation of hypoxia, DNA repair, damage and reduction of apoptosis, enhancement of EMT processes , the presence of cancer stem cells (CSCs) and aberrant activation of key signaling pathways .
-
Immunity: B7H3/B7H4 is expected to become a new target for colorectal cancer immunotherapy
Time of Update: 2022-04-24
In mouse experiments, antibody-mediated blockade or genetic deletion of members of this pathway inhibited tumor development and promoted regression of metastatic colorectal cancers, demonstrating that perturbation of members of this pathway activates CD8 + T cell-dependent Antitumor immunity and durable disease control .
-
Clin Cancer Res: Efficacy of the FGFR inhibitor Infigratinib as monotherapy in the treatment of recurrent gliomas with EGFR mutations
Time of Update: 2022-04-24
Approximately 8% of gliomas harbor fibroblast growth factor receptor (FGFR) genomic variants (amplifications, mutations, and/or fusions), particularly EGFR1 and EGFR2 .
About 8% of gliomas diagnosed carry fibroblast growth factor receptor (FGFR) genomic variants (amplifications, mutations, and/or fusions), particularly EGFR1 and EGFR2 .